The Maryland Citizens' Health Initiative, a coalition of more than 1,200 religious, labor, business and policy groups seeking quality and affordable health care, wants the state Legislature to address high drug costs by overhauling some of the laws governing drug pricing.
The Center for American Progress released a paper Monday outlining a method for pricing drugs based on their value through the use of comparative-effectiveness research and an arbitration process.
The company said Monday it believes it is best positioned to maximize shareholder value in its current form, but it reserves the right to split in the future if the situation changes.
Federal regulators have approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases.
Mylan CEO Heather Bresch's recent announcement that Mylan is looking to extend the shelf life of the EpiPen could be a relief for patients, but a costly move for Mylan since it may take significant research and development to change epinephrine, the drug inside the EpiPen.
Outraged Republican and Democratic lawmakers on Wednesday grilled the head of pharmaceutical company Mylan about the significant cost increase of its life-saving EpiPens and the profits for a company with sales in excess of $11 billion.
Botox-maker Allergan is bulking up its drug pipeline by acquiring Tobira Therapeutics and two potential liver disease treatments in a deal that could be worth almost $1.7 billion.
Drugmaker GlaxoSmithKline says Emma Walmsley will be the company's new chief executive, replacing Andrew Witty when he retires next March.
Laboratory Corporation of America has announced the next CEO of its Covance drug development division, just two weeks after Deborah Keller announced she would resign.
Republicans on the Senate Finance Committee have joined the chorus calling for an investigation into Medicaid's handling of manufacturer rebates for EpiPen.
The FDA has granted tentative approval to a highly contested drug for muscular dystrophy that has become a flashpoint in the debate over patient access to experimental medicine.
HHS on Friday finalized a rule that expands and clarifies what clinical-trial data legally needs to be made public. The goal is to help scientists, doctors and patients learn more about ongoing research and potentially ease access to experimental treatments.